BindingDB logo
myBDB logout

null

SMILES: COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cc-2ccn3)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1

InChI Key: InChIKey=FHSHZYQPCHWIHY-NRFANRHFSA-N

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 357096   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Coagulation factor XI


(Homo sapiens (Human))
BDBM357096
PNG
(US10214512, Example 73)
Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cc-2ccn3)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 |r|
Show InChI InChI=1S/C30H25ClF2N4O4/c1-41-30(39)35-19-7-8-20-17-12-13-34-24(14-17)21(4-2-3-5-27(38)36-25(20)15-19)26-11-6-18(16-37(26)40)28-23(32)10-9-22(31)29(28)33/h6-16,21H,2-5H2,1H3,(H,35,39)(H,36,38)/t21-/m0/s1
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
0.340n/an/an/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...


US Patent US10214512 (2019)


BindingDB Entry DOI: 10.7270/Q2668GGN
More data for this
Ligand-Target Pair
Kallikrein-1


(Homo sapiens (Human))
BDBM357096
PNG
(US10214512, Example 73)
Show SMILES COC(=O)Nc1ccc-2c(NC(=O)CCCC[C@@H](c3cc-2ccn3)c2ccc(c[n+]2[O-])-c2c(F)ccc(Cl)c2F)c1 |r|
Show InChI InChI=1S/C30H25ClF2N4O4/c1-41-30(39)35-19-7-8-20-17-12-13-34-24(14-17)21(4-2-3-5-27(38)36-25(20)15-19)26-11-6-18(16-37(26)40)28-23(32)10-9-22(31)29(28)33/h6-16,21H,2-5H2,1H3,(H,35,39)(H,36,38)/t21-/m0/s1
PDB

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
1.08n/an/an/an/an/an/an/an/a



Merck Sharp & Dohme Corp.

US Patent


Assay Description
The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...


US Patent US10214512 (2019)


BindingDB Entry DOI: 10.7270/Q2668GGN
More data for this
Ligand-Target Pair